Craneware (LON:CRW) Reaches New 52-Week High at $2,400.00

Craneware plc (LON:CRW) reached a new 52-week high during trading on Wednesday . The company traded as high as GBX 2,400 ($30.15) and last traded at GBX 2,370 ($29.77), with a volume of 21653 shares changing hands. The stock had previously closed at GBX 2,380 ($29.90).

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upped their price objective on shares of Craneware from GBX 2,300 ($28.89) to GBX 2,600 ($32.66) and gave the company a “buy” rating in a research note on Monday, March 4th.

Craneware Stock Performance

The company has a quick ratio of 1.00, a current ratio of 0.78 and a debt-to-equity ratio of 19.15. The firm has a 50-day simple moving average of GBX 2,196.17 and a 200 day simple moving average of GBX 1,949.96. The company has a market cap of £847.92 million, a price-to-earnings ratio of 11,333.33 and a beta of 0.13.

Craneware Cuts Dividend

The firm also recently announced a dividend, which was paid on Monday, April 15th. Stockholders of record on Thursday, March 21st were issued a GBX 13 ($0.16) dividend. The ex-dividend date of this dividend was Thursday, March 21st. This represents a dividend yield of 0.62%. Craneware’s payout ratio is 13,809.52%.

About Craneware

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors.